Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP271758.RAd40AwIKxViTRYPLsv0CqIkZLG6Ns2nl9jU61sdfOdsI130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP271758.RAd40AwIKxViTRYPLsv0CqIkZLG6Ns2nl9jU61sdfOdsI130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP271758.RAd40AwIKxViTRYPLsv0CqIkZLG6Ns2nl9jU61sdfOdsI130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP271758.RAd40AwIKxViTRYPLsv0CqIkZLG6Ns2nl9jU61sdfOdsI130_provenance.
- NP271758.RAd40AwIKxViTRYPLsv0CqIkZLG6Ns2nl9jU61sdfOdsI130_assertion description "[The phase II SRC/ABL Tyrosine Kinase Inhibition Activity Research Trials (START) of dasatinib have established dasatinib as potent and effective in overcoming imatinib resistance or intolerance in all phases of CML.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP271758.RAd40AwIKxViTRYPLsv0CqIkZLG6Ns2nl9jU61sdfOdsI130_provenance.
- NP271758.RAd40AwIKxViTRYPLsv0CqIkZLG6Ns2nl9jU61sdfOdsI130_assertion evidence source_evidence_literature NP271758.RAd40AwIKxViTRYPLsv0CqIkZLG6Ns2nl9jU61sdfOdsI130_provenance.
- NP271758.RAd40AwIKxViTRYPLsv0CqIkZLG6Ns2nl9jU61sdfOdsI130_assertion SIO_000772 18397680 NP271758.RAd40AwIKxViTRYPLsv0CqIkZLG6Ns2nl9jU61sdfOdsI130_provenance.
- NP271758.RAd40AwIKxViTRYPLsv0CqIkZLG6Ns2nl9jU61sdfOdsI130_assertion wasDerivedFrom befree-20140225 NP271758.RAd40AwIKxViTRYPLsv0CqIkZLG6Ns2nl9jU61sdfOdsI130_provenance.
- NP271758.RAd40AwIKxViTRYPLsv0CqIkZLG6Ns2nl9jU61sdfOdsI130_assertion wasGeneratedBy ECO_0000203 NP271758.RAd40AwIKxViTRYPLsv0CqIkZLG6Ns2nl9jU61sdfOdsI130_provenance.
- befree-20140225 importedOn "2014-02-25" NP271758.RAd40AwIKxViTRYPLsv0CqIkZLG6Ns2nl9jU61sdfOdsI130_provenance.